Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder (original) (raw)
References
- Akhondzadeh SH, Tvakolian R, Davari-Ashtiani R, Arabgol F, Amini H (2003) Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double-blind and randomized trial. Prog Neuro-Psychopharmacol Bio Psychiatry 27:841–845
Article CAS Google Scholar - American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. Text revised (DSM-VI-TR). American Psychiatric Association. Washington
- Banaschewski T, Roessener V, Dittman RW, Santsho PJ, Rothenberger A (2004) Non stimulant medications in the treatment of ADHD. In: Taylor E, Dopfner M, Sergeant J, Asherson PH, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Stenhausen H-CH, Zuddas A (2004) European clinical guideline for hyperkinetic disorder—first upgrade. Eur Child Adolesc Psychiatry 13(Suppl 1):1/7–1/30
Google Scholar - Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Dopfner M, V.Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E (2006) Long-acting medications for the hyperkinetic disorders, a systemic review and European treatment guideline. Eur Child Adolesc Psychiatry 15:476–495
Article PubMed Google Scholar - Biederman J, Spenser T, Wilentst T (2004) Evidence-based pharmacotherapy for attention deficit hyperactivity disorder. Int Neurophsychopharmacol 7:77–97
Article CAS Google Scholar - Bock N, Quentin DJ, Hüther G, Moll GH, Banaschewski T, Rothenberger A (2005) Very early treatment with fluoxetine and reboxetine causing long lasting changes of the serotonin but not the noradrenaline transporter in the frontal cortex of rats. World J Biol Psychiatry 6:107–112
Article PubMed Google Scholar - Bymaster FP, Katner J, Nelson DL, et al (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder In: E- Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Barker KD, Feldman PD, Gelowitz DL (2006). Effects of long-term atomoxetine treatment for young children with attention deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:919–927
- De Battista C, Schatzberg AF (2005) Other pharmacological and biological therapies. In: Sadock BJ, Sadock VA (eds) Comprehensive textbook of psychiatry, 8th edn, Lippincatt Williams & Wilkins, Baltimore, p 2997
Google Scholar - Dupaul GJ (1991) Parent and teacher rating of ADHD symptoms: psychometric properties in a community based sample. J Clin Child Psychol 20:245–253
Article Google Scholar - Edwards DM, Pellizoni C, Breuel HP, Beraridi A, Catelli MG, Frigerio E, Poggesi I, Rocchetti M, Dubini A, Strolin Benedetti M (1995) Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses. Linearity and plasma protein binding. Biopharm Drug Dispos 16:443–460
Article PubMed CAS Google Scholar - Gilberg C, Melander H, Knorring A (1997) Long term stimulant treatment of children with attention deficit hyperactivity disorder symptoms. Arch Gen Psychiatry 54:857–864
Google Scholar - Kehpe WA (2001) Treatment of attention deficit hyperactivity disorder in children. Ann pharmacother 35:1130–1134
Article Google Scholar - Klein RG, Landa B (1988) Methylphenidate and growth in hyperactive children. Arch Gen Psychiatry 45:1127–1130
PubMed CAS Google Scholar - Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Barker KD, Feldman PD, Gelowitz DL (2006) Effects of long-term atomoxetine treatment for young children with attention deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:919–927
Article PubMed Google Scholar - Massino M (1997) Reboxetine: a review of antidepressant tolerability. J Psychopharm 11(Suppl 4):S33–S37
Google Scholar - Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T, Atomoxetine ADHD study group (2001) Atomoxetin in the treatment of children and adolescent with attention deficit hyperactivity disorder: a randomized placebo-controlled dose-response study. Pediatrics 108:E83
Article PubMed CAS Google Scholar - Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D (2002) Once-daily atomoxetine treatment for children and adolescent with attention deficit hyperactivity disorder: a randomized placebo-controlled study. Am J Psychiatry 159:1896–1901
Article PubMed Google Scholar - Mozes T, Meiri G, Ben-Amity G, Sabbagh M, Weizman A (2005) Reboxetine as an optimal treatment for hyperactive conduct disorder: a prospective open-label trial. J Child Adolesc Psychopharmacol 15:259–269
Article PubMed Google Scholar - Otka JE, Mercadante MT, Scahill L, Leckman JF (2001) Reboxetine as a potentially effective treatment for attention deficit hyperactivity disorder [letter to the editor]. J Child Adolesc Psychopharmacol 11:203–204
Article PubMed CAS Google Scholar - Pataki C, Carlson G (1993) Side effects of methylphenidate and desipramine alone and in combination in children. J Am Acad Child Adolesc Psychiatry 32:1065–1082
Article PubMed CAS Google Scholar - Prince JB, Wilens TE, Biederman J (2000) A controlled study of nortriptyline in children and adolescent with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 10:193–204
Article PubMed CAS Google Scholar - Klein RG, Abikoff H, Barkely RA, Campbell M, Leckman JF, Ryan ND, Solanto MV, Whalen CK (1994) Clinical trial in children and adolescents. In: Clinical evaluation of psychotherapic drugs: principles and guidelines. Edited by Prien RF, Rabinson DS. New York, Raven press, pp 501–546
- Ratner SH, Laor N, Bronstein Y, Weizman A,Toren P (2005) Six week open-label reboxetine treatment in children and adolescents with attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 44:428–433
Article PubMed Google Scholar - Sadock BJ, Sadock VA (2007) Kaplan and sadock’s synopsis of psychiatry: behavioral sciences/clinical psychiatry, 10th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1206–1217
Google Scholar - Safer DJ (1997) Central stimulant treatment of childhood attention deficit hyperactivity disorder across the life cycle. CNS Drugs 7:264–272
Article Google Scholar - Spencer T, Biederman J, Wilens T, Harding M, O’Donnell D, Griffins S (1996) Pharmacotherapy of attention deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35:409–432
Article PubMed CAS Google Scholar - Spencer T, Biederman J, Wilens T (2004) Nonstimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatr Clin N Am 27:373–383
Article Google Scholar - Taylor E, Dopfner M, Sergeant J, Asherson PH, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Stenhausen H-CH, Zuddas A (2004) European clinical guideline for hyperkinetic disorder—first upgrade. Eur Child Adolesc Psychiatry 13(Suppl 1):1/7–1/30
Google Scholar - Tenreiro K (2001) Methylphenidate-placebo: a trial for attention deficit disorders. Int J Pharm Compd 5:21–22
Google Scholar - Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R (1999) Reboxetine, a unique selective NRI, prevents relapse and recurrence in long term treatment of major depressive disorder In: Mozes T, Meiri G, Ben-Amity G, Sabbagh M, Weizman A (2005) Reboxetine as an optimal treatment for hyperactive conduct disorder: a prospective open-label trial. J Child Adolesc Psychopharmacol 15:259–269
Google Scholar - Weiss M, Weiss G (1996) Attention deficit hyperactivity disorder. In: Lewis M (eds) Child and adolescent psychiatry, 3rd edn. Williams and Wilkins, Baltimore, pp 645–670
Google Scholar - Wilens TE, Biederman J (1992) The stimulants. Psychiatr Clin N Am 90:191–222
Google Scholar